Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 10825478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection.

  1999cited by this paper
• Adenovirus-mediated Expression of an Olfactory Cyclic Nucleotide-gated Channel Regulates the Endogenous Ca2+-inhibitable Adenylyl Cyclase in C6-2B Glioma Cells*

  1999cited by this paper
• alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.

  1999cited by this paper
• Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance?

  1999cited by this paper
• Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein.

  1999cited by this paper
• Parkinson's disease--a multifactorial neurodegenerative disorder.

  1999cited by this paper
• Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex.

  1999cited by this paper
• Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro.

  1999cited by this paper
• alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

  1999cited by this paper
• Copper(II)-induced self-oligomerization of alpha-synuclein.

  1999cited by this paper
• Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation*

  1999cited by this paper
• Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions.

  1999cited by this paper
• Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro *

  1999cited by this paper
• Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease

  1998cited by this paper
• Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity

  1998cited by this paper
• Improvement of neurological deficits in 6-hydroxydopamine-lesioned rats after transplantation with allogeneic simian virus 40 large tumor antigen gene-induced immortalized dopamine cells.

  1998cited by this paper
• Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein

  1998cited by this paper
• The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease.

  1998cited by this paper
• Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35).

  1998cited by this paper
• Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development.

  1998cited by this paper
• Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

  1998cited by this paper
• Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

  1998cited by this paper
• Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments

  1998cited by this paper
• alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

  1998cited by this paper
• Alpha synuclein in neurodegenerative disorders: Murderer or accomplice?

  1998cited by this paper
• Epidemiology versus genetics in parkinson's disease: Progress in resolving an age‐old debate

  1998cited by this paper
• Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

  1997cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Rapid and efficient one-tube PCR-based mutagenesis method.

  1997cited by this paper
• Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC.

  1997cited by this paper
• Mechanism of 6-hydroxydopamine neurotoxicity.

  1997cited by this paper
• Growth factors rescue embryonic dopamine neurons from programmed cell death.

  1996cited by this paper
• NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.

  1996cited by this paper
• Characterization and transplantation of two neuronal cell lines with dopaminergic properties

  1996cited by this paper
• Methods for construction of adenovirus vectors

  1995cited by this paper
• NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.

  1995cited by this paper
• Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

  1995cited by this paper
• Efficient selection of recombinant adenoviruses by vectors that express beta-galactosidase

  1995cited by this paper
• Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

  1993cited by this paper
• Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture

  1990cited by this paper
• Neuropathology in movement disorders.

  1989cited by this paper
• The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

  1988cited by this paper
• Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

  1977cited by this paper

• Interaction Between α-Synuclein and DJ-1 in Parkinson’s Disease

  2025cites this paper
• Autoantibodies against α-synuclein inhibit its aggregation and cytotoxicity.

  2025cites this paper
• Effects of neural stem cell-derived exosomes on MPTP-induced Parkinson’s disease in mice

  2025cites this paper
• Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease

  2025cites this paper
• Dopaminergic system and neurons: Role in multiple neurological diseases.

  2024cites this paper
• Black Phosphorus Nanosheets Protect Neurons by Degrading Aggregative α‐syn and Clearing ROS in Parkinson's Disease

  2024cites this paper
• An optimized Nurr1 agonist provides disease-modifying effects in Parkinson’s disease models

  2023cites this paper
• STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease.

  2023influential citation
• Gut-Brain Axis Deregulation and Its Possible Contribution to Neurodegenerative Disorders

  2023cites this paper
• Alteration of EIF2 Signaling, Glycolysis, and Dopamine Secretion in Form-Deprived Myopia in Response to 1% Atropine Treatment: Evidence From Interactive iTRAQ-MS and SWATH-MS Proteomics Using a Guinea Pig Model

  2022cites this paper
• Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson’s Disease

  2022cites this paper
• A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.

  2021cites this paper
• Targeting Autophagy In Disease: Recent Advances In Drug Discovery

  2020cites this paper
• In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies

  2019cites this paper
• α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.

  2019cites this paper
• Dopaminergic neuron injury in Parkinson’s disease is mitigated by interfering lncRNA SNHG14 expression to regulate the miR-133b/ α-synuclein pathway

  2019cites this paper
• Tyrosine hydroxylase phosphorylation in vivo

  2019cites this paper
• Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy

  2018cites this paper
• The Role of LRRK2 in Neurodegeneration of Parkinson Disease

  2018cites this paper
• Exogenous α-synuclein hinders synaptic communication in cultured cortical primary rat neurons

  2018cites this paper
• Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.

  2017cites this paper
• Glutamine promotes Hsp70 and inhibits α-Synuclein accumulation in pheochromocytoma PC12 cells.

  2017cites this paper
• Tristetraprolin inhibits mitochondrial function through suppression of α-Synuclein expression in cancer cells

  2017cites this paper
• Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.

  2017cites this paper
• α-Synuclein binds to cytoplasmic vesicles in U251 glioblastoma cells.

  2017cites this paper
• Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease.

  2017cites this paper
• MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions

  2017cites this paper
• Inhibition of α-Synuclein contributes to the ameliorative effects of dietary flavonoids luteolin on arsenite-induced apoptotic cell death in the dopaminergic PC12 cells

  2017cites this paper
• Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases

  2017cites this paper
• The interaction of small heat shock molecular chaperone proteins with a-synuclein

  2016cites this paper
• ALPHA-SYNUCLEIN STRUCTURE, AGGREGATION AND MODULATORS

  2016cites this paper
• Alpha-synuclein-induced oxidative stress correlates with altered superoxide dismutase and glutathione synthesis in human neuroblastoma SH-SY5Y cells

  2016cites this paper
• Up-regulation of SNCA gene expression: implications to synucleinopathies

  2016cites this paper
• Endolysosomal Dysfunction in Parkinson Disease: The Role of Disease Mutations in ATP13A2 and LRRK2.

  2016cites this paper
• Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia

  2016cites this paper
• Neurons Self-Organize Around Salivary Epithelial Cells in Novel Co-Culture Model

  2016cites this paper
• Familial Parkinson Disease-associated Mutations Alter the Site-specific Microenvironment and Dynamics of α-Synuclein*

  2015cites this paper
• Parkinson's disease as a member of Prion-like disorders.

  2015cites this paper
• Redox regulation of NF‐κB p50 and M1 polarization in microglia

  2015cites this paper
• Targeting a custom-engineered flavonoid to the mitochondria protects against acute oxidative stress

  2015cites this paper
• Dimerization propensities of Synucleins are not predictive for Synuclein aggregation.

  2015cites this paper
• Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons

  2015cites this paper
• Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underling cellular aggregation

  2014cites this paper
• Dopamine Cytotoxicity Involves Both Oxidative and Nonoxidative Pathways in SH-SY5Y Cells: Potential Role of Alpha-Synuclein Overexpression and Proteasomal Inhibition in the Etiopathogenesis of Parkinson's Disease

  2014cites this paper
• Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease

  2014cites this paper
• Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins.

  2014cites this paper
• RE SEARCH ARTICLE DEVELOPING ARGININE AS AN INHIBITOR FOR A - SYNUCLEIN AGGREG ATION: AN INNOVATIVE THERAPY TO COMBAT PARKINSON'S DISEASE

  2014cites this paper
• DEVELOPING ARGININE AS AN INHIBITOR FOR Α-SYNUCLEIN AGGREGATION: AN INNOVATIVE THERAPY TO COMBAT PARKINSON’S DISEASE

  2014cites this paper
• A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.

  2014cites this paper
• Chemical induction of Hsp70 reduces α-synuclein aggregation in neuroglioma cells.

  2013cites this paper
• Evaluation of a-Synuclein Degradation Pathways in a Budding Yeast Model

  2013cites this paper
• Genetic and pharmacological manipulations of the serotonergic system in early life: neurodevelopmental underpinnings of autism-related behavior

  2013cites this paper
• “Green” Synthesized and Coated Nanosilver Alters the Membrane Permeability of Barrier (Intestinal, Brain Endothelial) Cells and Stimulates Oxidative Stress Pathways in Neurons

  2013cites this paper
• Particulate matter neurotoxicity in culture is size-dependent.

  2013cites this paper
• A loss in cellular protein partners promotes α-synuclein aggregation in cells resulting from oxidative stress.

  2013cites this paper
• Can Intrabodies Serve as Neuroprotective Therapies for Parkinson's Disease? Beginning Thoughts

  2013cites this paper
• Nanoneurotoxicity to Nanoneuroprotection Using Biological and Computational Approaches

  2013cites this paper
• C-terminal binding proteins are essential pro-survival factors that undergo caspase-dependent downregulation during neuronal apoptosis.

  2013cites this paper
• The remarkable conformational plasticity of alpha-synuclein: blessing or curse?

  2013cites this paper
• Quantitative Analysis of α-Synuclein Solubility in Living Cells Using Split GFP Complementation

  2012cites this paper
• Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson's disease.

  2012cites this paper
• Interplay between Alpha-Synuclein and Oxidative Stress in Parkinson´s Disease Cell Models

  2012cites this paper
• α Aggregation and Modulating Factors

  2012cites this paper
• Remodeling of Lipid Vesicles into Cylindrical Micelles by α-Synuclein in an Extended α-Helical Conformation*

  2012cites this paper
• α-Synuclein aggregation and modulating factors.

  2012cites this paper
• Oxidative Stress in Neurodegeneration

  2011cites this paper
• Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKCδ in cell culture and animal models of Parkinson's disease.

  2011cites this paper
• α-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-κB-mediated pathway

  2011cites this paper
• α-Synuclein Stimulates a Dopamine Transporter-dependent Chloride Current and Modulates the Activity of the Transporter*

  2011cites this paper
• The oxysterol 27‐hydroxycholesterol regulates α‐synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors–relevance to Parkinson’s disease

  2011cites this paper
• Phenylbutyrate Up-regulates the DJ-1 Protein and Protects Neurons in Cell Culture and in Animal Models of Parkinson Disease*

  2011cites this paper
• Necrosis, Apoptosis, and Autophagy: Mechanisms of Neuronal and Glial Cell Death

  2011cites this paper
• The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.

  2011cites this paper
• Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein*♦

  2011cites this paper
• Expression of mutant alpha-synuclein modulates microglial phenotype in vitro

  2011cites this paper
• Different sub-cellular localization of alpha-synuclein in the C57BL\6J mouse's central nervous system by two novel monoclonal antibodies.

  2011cites this paper
• Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.

  2011cites this paper
• Drug discovery in Parkinson’s disease: update and developments in the use of cellular models

  2011cites this paper
• Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies.

  2011cites this paper
• Protein Kinase C-Dependent Dephosphorylation of Tyrosine Hydroxylase Requires the B56δ Heterotrimeric Form of Protein Phosphatase 2A

  2011cites this paper
• Establishment of Stably Transfected Rat Neuronal Cell Lines Expressing α-Synuclein GFP Fusion Proteins

  2010cites this paper
• The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson’s disease

  2010cites this paper
• Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity

  2010cites this paper
• Ubiquitylation of Neuronal Pentraxin with Chromo Domain by the E3 Ubiquitin Ligase Mayven/KLHL2 and Effec ts on Aggresome Formation and Neuronal Cytotoxicity

  2010cites this paper
• Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity.

  2010cites this paper
• alpha-Synuclein overexpression during manganese-induced apoptosis in SH-SY5Y neuroblastoma cells.

  2010cites this paper
• Increased Expression of a-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis

  2010cites this paper
• Simple is good: yeast models of neurodegeneration.

  2010cites this paper
• Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice.

  2010cites this paper
• Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.

  2010cites this paper
• α-Synuclein and neuronal cell death

  2009cites this paper
• Intrabody and Parkinson's disease.

  2009cites this paper
• Neuroprotective Effects of Chalcones from Myracrodruon urundeuva on 6-Hydroxydopamine-Induced Cytotoxicity in Rat Mesencephalic Cells

  2009cites this paper
• Pre‐fibrillar α‐synuclein variants with impaired β‐structure increase neurotoxicity in Parkinson's disease models

  2009cites this paper
• Molecular mechanisms of alpha-synuclein neurodegeneration.

  2009cites this paper
• Partial oxidation ("aging") and surface modification decrease the toxicity of nanosized zerovalent iron.

  2009cites this paper
• Inducible over‐expression of wild type α‐synuclein in human neuronal cells leads to caspase‐dependent non‐apoptotic death

  2009cites this paper
• Molecular and Neurochemical Mechanisms in PD Pathogenesis

  2009cites this paper
• Embryonic Stem Cells with GFP Knocked into the Dopamine Transporter Yield Purified Dopamine Neurons In Vitro and from Knock‐In Mice

  2009cites this paper
• Adenoviral Gene Delivery Can Reprogram Human Fibroblasts to Induced Pluripotent Stem Cells

  2009cites this paper